Big pharma Watson Pharmaceuticals Inc. (WPI) might announce a deal to buy Actavis for around $6 billion on Wednesday, the Reuters news agency said Monday on its website, citing unnamed sources familiar with the matter.
The deal, first reported in March, is likely to be valued at EUR 4.25 billion ($5.6 billion), less than the expected EUR 5-5.5 billion, the report said, citing a source.
Read more: Link no longer active
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
Read: Big pharma deal news - latest deal news for top 50 pharma / big pharma companies
Report: Partnering Deals and Alliances with Actavis (formerly Watson Pharmaceuticals)
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity